A Phase II Study of Tri-weekly XELIRI with Bevacizumab for patient with unresectable or recurrent Colorectal Cancer as first -line chemotherapy.
收藏NIAID Data Ecosystem2026-03-07 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2621504
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Tri-weekly XELIRI+ bevacizumab
Primary outcome(s): Response rate
Study Design: Single arm Non-randomized
创建时间：
2011-07-15
